Specialty Pharma

Through investments in product development, collaborative research, and acquisitions, we are expanding our portfolio of proprietary medicines. In a relatively short time, we have built a significant pipeline for Unimedic Pharma, and we remain focused on continuing this work. At the same time, we are evaluating complementary acquisitions of well-established and medically well-justified products.